Abstract | BACKGROUND: METHODS AND DESIGN: ALTAIR is a phase IV, open-label, randomized, parallel-group, single-center study involving blinded optical coherence tomography (OCT) image analysis in Japanese adults hospitalized for PCI and having suboptimal control of low-density lipoprotein cholesterol ( LDL-C) levels (>70mg/dL) despite statin therapy. Patients will be randomized (1:1) to the alirocumab arm ( alirocumab 75mg every 2 weeks added to rosuvastatin 10mg/day) or the standard-of-care arm ( rosuvastatin 10mg/day, with initiation and/or dose adjustment of non- statin lipid-lowering to achieve an LDL-C target of <70mg/dL). OCT imaging will be conducted at baseline and at week 36 (post-treatment). The primary objective is to compare the alirocumab and standard-of-care arms regarding the change in TCFA fibrous-cap thickness after 9 months of treatment. CONCLUSION: The outcomes of ALTAIR (ClinicalTrials.gov identifier: NCT03552432) will provide insights into the effect of alirocumab on plaque vulnerability following PCI in patients with suboptimal LDL-C control despite stable statin therapy.
|
Authors | Hiromasa Otake, Yoichiro Sugizaki, Takayoshi Toba, Yuichiro Nagano, Yoshiro Tsukiyama, Ken-Ichi Yanaka, Hiroyuki Yamamoto, Akira Nagasawa, Hiroyuki Onishi, Ryo Takeshige, Shinsuke Nakano, Yoichiro Matsuoka, Kosuke Tanimura, Hiroyuki Kawamori, Toshiro Shinke, Ken-Ichi Hirata |
Journal | Journal of cardiology
(J Cardiol)
Vol. 73
Issue 3
Pg. 228-232
(03 2019)
ISSN: 1876-4738 [Electronic] Netherlands |
PMID | 30579806
(Publication Type: Clinical Trial Protocol, Journal Article)
|
Copyright | Copyright © 2018 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Anticholesteremic Agents
- Cholesterol, LDL
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Rosuvastatin Calcium
- alirocumab
|
Topics |
- Adult
- Antibodies, Monoclonal, Humanized
(administration & dosage)
- Anticholesteremic Agents
(administration & dosage)
- Cholesterol, LDL
(blood)
- Coronary Artery Disease
(complications, diagnostic imaging, drug therapy)
- Drug Therapy, Combination
- Female
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(administration & dosage)
- Japan
- Male
- Middle Aged
- Percutaneous Coronary Intervention
- Plaque, Atherosclerotic
(complications, diagnostic imaging, drug therapy)
- Postoperative Period
- Randomized Controlled Trials as Topic
- Rosuvastatin Calcium
(administration & dosage)
- Tomography, Optical Coherence
- Treatment Outcome
|